Tags

Type your tag names separated by a space and hit enter

Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-2019.
J Comp Eff Res. 2020 12; 9(18):1247-1254.JC

Abstract

Dexamethasone was shown to decrease the mortality in coronavirus disease-2019 (COVID-19) recently. Use of corticosteroids was harmful in other coronavirus infections previously. WHO recommended against routine use of corticosteroids in COVID-19. In view of these, we reviewed the evidence about the use of corticosteroids in virus-induced acute respiratory distress syndrome (ARDS). Corticosteroids are beneficial in ARDS regardless of etiology. However, they increased the mortality rate in influenza-associated ARDS. In SARS and the Middle East respiratory syndrome, corticosteroids increased the mortality, delayed the viral clearance and increased the length of hospital stay. In the case of COVID-19, the available evidence from retrospective and observational studies is inconclusive about the corticosteroid use. Low-dose therapies appear to be effective. Evidence from a randomized control study found dexamethasone is effective in decreasing mortality in severe COVID-19 cases. More studies are needed to validate the benefit of corticosteroids in COVID-19.

Authors+Show Affiliations

Strategic Center for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia.Strategic Center for Diabetes Research, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33245242

Citation

Rafiullah, Mohamed, and Khalid Siddiqui. "Corticosteroid Use in Viral Pneumonia: Experience so Far and the Dexamethasone Breakthrough in Coronavirus Disease-2019." Journal of Comparative Effectiveness Research, vol. 9, no. 18, 2020, pp. 1247-1254.
Rafiullah M, Siddiqui K. Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-2019. J Comp Eff Res. 2020;9(18):1247-1254.
Rafiullah, M., & Siddiqui, K. (2020). Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-2019. Journal of Comparative Effectiveness Research, 9(18), 1247-1254. https://doi.org/10.2217/cer-2020-0146
Rafiullah M, Siddiqui K. Corticosteroid Use in Viral Pneumonia: Experience so Far and the Dexamethasone Breakthrough in Coronavirus Disease-2019. J Comp Eff Res. 2020;9(18):1247-1254. PubMed PMID: 33245242.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-2019. AU - Rafiullah,Mohamed, AU - Siddiqui,Khalid, Y1 - 2020/11/27/ PY - 2020/11/28/pubmed PY - 2021/1/5/medline PY - 2020/11/27/entrez KW - ARDS KW - COVID-19 KW - acute respiratory distress syndrome KW - coronavirus KW - corticosteroids KW - dexamethasone KW - pneumonia SP - 1247 EP - 1254 JF - Journal of comparative effectiveness research JO - J Comp Eff Res VL - 9 IS - 18 N2 - Dexamethasone was shown to decrease the mortality in coronavirus disease-2019 (COVID-19) recently. Use of corticosteroids was harmful in other coronavirus infections previously. WHO recommended against routine use of corticosteroids in COVID-19. In view of these, we reviewed the evidence about the use of corticosteroids in virus-induced acute respiratory distress syndrome (ARDS). Corticosteroids are beneficial in ARDS regardless of etiology. However, they increased the mortality rate in influenza-associated ARDS. In SARS and the Middle East respiratory syndrome, corticosteroids increased the mortality, delayed the viral clearance and increased the length of hospital stay. In the case of COVID-19, the available evidence from retrospective and observational studies is inconclusive about the corticosteroid use. Low-dose therapies appear to be effective. Evidence from a randomized control study found dexamethasone is effective in decreasing mortality in severe COVID-19 cases. More studies are needed to validate the benefit of corticosteroids in COVID-19. SN - 2042-6313 UR - https://www.unboundmedicine.com/medline/citation/33245242/Corticosteroid_use_in_viral_pneumonia:_experience_so_far_and_the_dexamethasone_breakthrough_in_coronavirus_disease_2019_ L2 - https://www.futuremedicine.com/doi/10.2217/cer-2020-0146?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -